具有抗抑郁活性的皮科莫拉级宏环TRPC5通道抑制剂的结构导向设计
Tong Che1,2, Yixiang Chen1,2, Xinyu Cheng1,2
1The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
研究人员开发了宏环TRPC5抑制剂,以克服设计用于脂质结合部位的药物的挑战. 强效和选择性化合物JDIC-127在治疗神经精神疾病方面表现有前途.
科学领域:
- 离子通道药理学 离子通道药理学
- 结构生物学是结构生物学.
- 药物发现 药物发现
背景情况:
- 离子通道中的脂质结合口袋对选择性小分子药物设计提出了挑战.
- 与抑郁症和焦虑相关的TRPC5通道是治疗点,但在当前药物中面临非点效应.
研究的目的:
- 通过结构引导的宏循环化来设计强效和选择性的TRPC5抑制剂.
- 为了克服小分子抑制剂在脂质主导的结合部位的局限性.
主要方法:
- 结构引导的宏循环化来设计TRPC5抑制剂.
- 低温电子显微镜 (cryo-EM) 和计算建模.
- 试验室中的强度和选择性测试.
主要成果:
- 开发了宏环TRPC5抑制剂,克服了脂质结合部位的挑战.
- JDIC-127显示出高强度 (374 pmol/L IC50) 和异常的选择性.
- 特异性归因于TRPC5 S5-S6直升机附近的独特相互作用,最大限度地减少了目标外活动.
结论:
- 宏循环可以稳定连接体构造,并增强对具有挑战性的结合位点的亲和力.
- JDIC-127是离子通道药理学中的宏环化概念验证.
- 这种方法为开发针对TRP通道和其他疾病的新疗法提供了路线图.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Design Example: Design of an Irrigation Channel
Design Example: Maintaining Level of an Embankment
Antidepressant Drugs: Overview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
